Discussion Aotearoa NZ has an unmet need for funded CAR T-cell therapies for B-cell non-Hodgkin lymphomas and other B-cell malignancies. As we expect CAR T-cell therapy to become a standard of care in the future, it is important that consideration is given to the perspectives of patients, support persons, clinicians and administrators, in the design of a national service.